EA
BIIB icon

Emerald Advisers’s Biogen BIIB Stock Holding History

Emerald Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Sell
5,990
-37
-0.6% -$7.08K 0.03% 142
2026
Q1 		$1.1M Hold
6,027
– – 0.04% 141
2025
Q4 		$1.06M Sell
6,027
-220
-4% -$35.9K 0.03% 137
2025
Q3 		$875K Buy
6,247
+3,066
+96% +$414K 0.03% 148
2025
Q2 		$400K Buy
+3,181
New +$396K 0.01% 191

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Emerald Advisers's BIIB Position: Q2 2026 in Review

Emerald Advisers reduced its Biogen (BIIB) stake by 0.61% in Q2 2026, selling an estimated $7.08K and leaving 5,990 shares worth $1.29M. The position accounts for 0.03% of the portfolio, ranked #142.

Emerald Advisers first reported a position in BIIB in Q2 2025 and has held it in 5 quarters since. 1,042 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Emerald Advisers held 5,990 shares of Biogen worth $1.29M as of Q2 2026.
  • Emerald Advisers sold 37 Biogen shares in Q2 2026, an estimated $7.08K.
  • Biogen made up 0.03% of Emerald Advisers's portfolio in Q2 2026, its #142 holding.
  • Emerald Advisers first reported a position in Biogen in Q2 2025 and has held it in 5 quarters since.
  • 1,042 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.